Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

ClinicalTrials.gov ID: NCT03672630

Public ClinicalTrials.gov record NCT03672630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.

Study identification

NCT ID: NCT03672630
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Kevin Winthrop; Other
Enrollment: 474 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 22, 2019 (Actual)
Primary completion: Jan 8, 2026 (Actual)
Completion: Jan 8, 2026 (Actual)
Last update posted: Feb 2, 2026

2019 – 2026

United States locations

U.S. sites: 25
U.S. states: 18
U.S. cities: 24

Facility	City	State	ZIP	Site status
Loma Linda University Medical Center	Loma Linda	California	92354	—
University of California, San Diego	San Diego	California	92103	—
University of California, San Francisco	San Francisco	California	94110	—
Stanford University	Stanford	California	94305	—
National Jewish Health	Denver	Colorado	80206	—
University of Miami	Miami	Florida	33136	—
Tampa VA Medical Center	Tampa	Florida	33612	—
Emory University	Atlanta	Georgia	30322	—
Kaiser Permanente Hawaii	Honolulu	Hawaii	96817	—
University of Iowa	Iowa City	Iowa	52242	—
University of Kansas	Kansas City	Kansas	66160	—
Louisina State University	New Orleans	Louisiana	70112	—
Johns Hopkins University	Baltimore	Maryland	21224	—
Mayo Clinic	Rochester	Minnesota	55905	—
Northwell Health	Manhasset	New York	11030	—
New York University	New York	New York	10016	—
Columbia University Medical Center	New York	New York	10032	—
University of North Carolina	Chapel Hill	North Carolina	27599	—
Oregon Health & Science University	Portland	Oregon	97239	—
Temple University	Philadelphia	Pennsylvania	19140	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Texas Health Science Center	Tyler	Texas	75708	—
University of Washington	Seattle	Washington	98104	—
Vancouver Clinic	Vancouver	Washington	98664	—
University of Wisconsin School of Medicine and Public Health	Madison	Wisconsin	53705	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03672630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 2, 2026 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03672630 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →